Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Berry Genomics Co.,Ltd (000710.SZ)
Beijing, TJ, CN
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcriptional regulation, single cell/spatial sequencing, animal and plant genome resequencing, genome denovo sequencing, and microbial sequencing, as well as big data services. The company serves various organizations and facilities, including hospitals, research institutions, universities, and enterprises throughout Mainland China, Hong Kong, Macao, Taiwan, Southeast Asia, the Middle East, and Australia. The company was founded in 2010 and is headquartered in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.45% | -7.84% | -11.09% | -29.04% | -27.88% | -21.88% | -38.96% | -23.64% | -74.36% | -60.59% | +71.35% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-13.8% Q1'26: -3.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-7.4% Q1'26: -200.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-14.6% Q1'26: -50.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-19.3% Q1'26: -7.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-13.0% ★ Q1'26: -4.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-3.4% ★ Q1'26: +1.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-2.89× Q1'26: -4.21× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|
| Revenue |
1.37B
est: 2.41B (-43.3%)
|
1.15B
est: 2.41B (-52.3%)
|
1.08B
est: 1.08B (+0.0%)
|
| EBITDA |
-166.61M
est: -40.32M (-313.2%)
|
-335.97M
est: -40.32M (-733.3%)
|
-84.35M
est: -58.90M (-43.2%)
|
| EBIT |
-258.74M
est: -239.01M (-8.3%)
|
-436.80M
est: -239.01M (-82.8%)
|
-160.59M
est: -133.08M (-20.7%)
|
| Net Income |
-248.93M
|
-427.20M
|
-192.43M
|
| SGA |
463.21M
est: 467.42M (-0.9%)
|
404.55M
est: 467.42M (-13.4%)
|
357.18M
est: 345.34M (+3.4%)
|
| EPS |
-0.81
|
-1.21
|
-0.54
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 3.6K | 0.48% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 8.2K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 402.8K | 0.06% |
| 4 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 647.35 | 0.22% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.0K | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.0K | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 461.93 | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 53.36 | 0.22% |
| 9 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 17.54 | 0.31% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 8.35 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daixing Zhou | Co-Founder & Chief Scientist | — | — |
| Dong Wang | Chief Financial Officer, Deputy GM & Director | — | male |
| Fei Xu | Secretary to the Board | — | male |
| Li Gao | Accounting Supervisor | — | — |
| Yang Gao | GM & Chairman | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 000710.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
